Heat Biologics, Inc. to Present at 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014

Live Webcast of Heat's Presentation on February 11, 2014 at 11:00 a.m. ET

CHAPEL HILL, NC -- (Marketwired) -- 02/04/14 -- Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that Jeff Wolf, Chief Executive Officer, will be presenting a Company overview at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 11:00 a.m. Eastern Time. Hosted by the Biotechnology Industry Organization (BIO), the 16th Annual BIO CEO & Investor Conference will take place February 10-11, 2014 at the Waldorf Astoria in New York City.

A live audio webcast of the presentation will be available in the Investor Relations section of the Heat Biologics' website at www.heatbio.com. The webcast presentation will be archived on the Company's website for 90 days following the event.

About BIO CEO & Investor Conference
The 16th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. The 2013 CEO & Investor Conference featured 1,380 partnering meetings, 148 company presentations, and 1,400 attendees, over half of which were investors.

About Heat Biologics, Inc.
Heat Biologics, Inc. is a clinical-stage biopharmaceutical company focused on developing its novel, "off-the-shelf" ImPACT therapeutic vaccines to combat a wide range of cancers. Our ImPACT Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat's HS-110 will be entering Phase 2 trials against non-small cell lung cancer and its HS-410 will be entering Phase 1/2 clinical trials against bladder cancer. For more information, please visit www.heatbio.com.

Forward Looking Statements
This press release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements regarding the potential for Heat's ImPACT Therapy. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability for Heat's ImPACT Therapy to perform as designed. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Heat Biologics, Inc. Contact Information:
Matthew Czajkowski
Chief Financial Officer
(919) 240 7133
Email Contact

Jenene Thomas
Investor Relations and Corporate Communications Advisor
Jenene Thomas Communications, LLC
(908) 938-1475
Email Contact

Source: Heat Biologics Inc

Released February 4, 2014